{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:21:35Z","timestamp":1792725695307,"version":"4.5.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of children with cerebral venous thrombosis (CVT) who participated in the EINSTEIN-Jr trial. Children with CVT were randomized (2:1), after initial heparinization, to treatment with rivaroxaban or standard anticoagulants (continued on heparin or switched to vitamin K antagonist). The main treatment period was 3 months. The primary efficacy outcome, symptomatic recurrent venous thromboembolism (VTE), and principal safety outcome, major or clinically relevant nonmajor bleeding,were centrally evaluated by blinded investigators. Sinus recanalization on repeat brain imaging was a secondary outcome. Statistical analyses were exploratory. In total, 114 children with confirmed CVT were randomized. All children completed the follow-up. None of the 73 rivaroxaban recipients and 1 (2.4%; CVT) of the 41 standard anticoagulant recipients had symptomatic, recurrent VTE after 3 months (absolute difference, 2.4%; 95% confidence interval [CI], \u22122.6% to 13.5%). Clinically relevant bleeding occurred in 5 (6.8%; all nonmajor and noncerebral) rivaroxaban recipients and in 1 (2.5%; major [subdural] bleeding) standard anticoagulant recipient (absolute difference, 4.4%; 95% CI, \u22126.7% to 13.4%). Complete or partial sinus recanalization occurred in 18 (25%) and 39 (53%) rivaroxaban recipients and in 6 (15%) and 24 (59%) standard anticoagulant recipients, respectively. In summary, in this substudy of a randomized trial with a limited sample size, children with CVT treated with rivaroxaban or standard anticoagulation had a low risk of recurrent VTE and clinically relevant bleeding. This trial was registered at clinicaltrials.gov as #NCT02234843.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003244","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T22:31:42Z","timestamp":1608330702000},"page":"6250-6258","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":117,"title":["Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)"],"prefix":"10.1182","volume":"4","author":[{"given":"Philip","family":"Connor","sequence":"first","affiliation":[{"name":"The Noah's Ark Children\u2019s Hospital for Wales, Cardiff, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte","family":"S\u00e1nchez van Kammen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonie W. A.","family":"Lensing","sequence":"additional","affiliation":[{"name":"Bayer AG, Wuppertal, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Chalmers","sequence":"additional","affiliation":[{"name":"Royal Hospital for Children, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4328-9612","authenticated-orcid":false,"given":"Kriszti\u00e1n","family":"K\u00e1llay","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Hege","sequence":"additional","affiliation":[{"name":"Riley Hospital For Children at Indiana University (IU) Health, Indianapolis, IN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-383X","authenticated-orcid":false,"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[{"name":"Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine (DIMED), Padua University Hospital, Padua, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Biss","sequence":"additional","affiliation":[{"name":"Department of Haematology, The Newcastle upon Tyne Hospitals, National Health Service (NHS) Foundation Trust, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1106-0987","authenticated-orcid":false,"given":"Fanny","family":"Bajolle","sequence":"additional","affiliation":[{"name":"M3C-Necker Enfants Malades, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-5805","authenticated-orcid":false,"given":"Damien","family":"Bonnet","sequence":"additional","affiliation":[{"name":"M3C-Necker Enfants Malades, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2820-9650","authenticated-orcid":false,"given":"Sebastian","family":"Grunt","sequence":"additional","affiliation":[{"name":"Division of Neuropediatrics, Development, and Rehabilitation, University Children\u2019s Hospital, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8004-4190","authenticated-orcid":false,"given":"Riten","family":"Kumar","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-3096","authenticated-orcid":false,"given":"Olga","family":"Lvova","sequence":"additional","affiliation":[{"name":"Ural Federal University, Ural State Medical University, Yekaterinburg, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukhmi","family":"Bhat","sequence":"additional","affiliation":[{"name":"Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Van Damme","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Saint Luc University Hospital, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Santamaria","sequence":"additional","affiliation":[{"name":"Hemostasis and Thrombosis Unit, Department of Hematology, University Hospital Vall d\u00b4Hebron, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Saracco","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, University Hospital Citt\u00e0 della Salute e della Scienza Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Payne","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology, Sheffield Children\u2019s Hospital, Sheffield, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Baird","sequence":"additional","affiliation":[{"name":"Royal Hospital for Sick Children, Edinburgh, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamar","family":"Godder","sequence":"additional","affiliation":[{"name":"Nicklaus Children\u2019s Hospital, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Labarque","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, University Hospital Leuven Gasthuisberg, Leuven, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-6421","authenticated-orcid":false,"given":"Christoph","family":"Male","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-3622","authenticated-orcid":false,"given":"Ida","family":"Martinelli","sequence":"additional","affiliation":[{"name":"A. Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda-Ospedale Maggiore Policlinico, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Morales Soto","sequence":"additional","affiliation":[{"name":"Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Motwani","sequence":"additional","affiliation":[{"name":"Birmingham Children\u2019s Hospital, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Shah","sequence":"additional","affiliation":[{"name":"University of Arizona School of Medicine and Phoenix Children\u2019s Hospital, Phoenix, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene L.","family":"Hooimeijer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Medical Center Groningen, Beatrix Children\u2019s Hospital, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Prins","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Kubitza","sequence":"additional","affiliation":[{"name":"Bayer AG, Wuppertal, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-4408","authenticated-orcid":false,"given":"Scott D.","family":"Berkowitz","sequence":"additional","affiliation":[{"name":"Bayer US, LLC, Whippany, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-3151","authenticated-orcid":false,"given":"Akos F.","family":"Pap","sequence":"additional","affiliation":[{"name":"Bayer AG, Wuppertal, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhurima","family":"Majumder","sequence":"additional","affiliation":[{"name":"Bayer US, LLC, Whippany, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Monagle","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Royal Children\u2019s Hospital,"},{"name":"Haematology Research Murdoch's Children's Research Institute, and"},{"name":"Department of Paediatrics, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Coutinho","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"issue":"6","key":"2020121716401781300_B1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM200108093450604","article-title":"Cerebral sinovenous thrombosis in children","volume":"345","author":"deVeber","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"2020121716401781300_B2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrneurol.2017.104","article-title":"Cerebral venous thrombosis","volume":"13","author":"Silvis","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"2020121716401781300_B3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/archdischild-2014-306382","article-title":"Paediatric cerebral sinovenous thrombosis: findings of the International Paediatric Stroke Study","volume":"100","author":"Ichord","year":"2015","journal-title":"Arch Dis Child"},{"issue":"11","key":"2020121716401781300_B4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1161\/01.CIR.0000087598.05977.45","article-title":"Cerebral venous thrombosis in children: a multifactorial origin","volume":"108","author":"Heller","year":"2003","journal-title":"Circulation"},{"issue":"pt 3","key":"2020121716401781300_B5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/brain\/awh412","article-title":"Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome","volume":"128","author":"S\u00e9bire","year":"2005","journal-title":"Brain"},{"issue":"12","key":"2020121716401781300_B6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1469-8749.2010.03722.x","article-title":"Cerebral sinus venous thrombosis in Swiss children","volume":"52","author":"Grunt","year":"2010","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"2020121716401781300_B7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.10.001","article-title":"Cerebral venous thrombosis: analysis of a multicenter cohort from the United States","volume":"17","author":"Wasay","year":"2008","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"10","key":"2020121716401781300_B8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ene.13381","article-title":"European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis-endorsed by the European Academy of Neurology","volume":"24","author":"Ferro","year":"2017","journal-title":"Eur J Neurol"},{"issue":"4","key":"2020121716401781300_B9","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/STR.0b013e31820a8364","article-title":"Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Saposnik","year":"2011","journal-title":"Stroke"},{"issue":"8767","key":"2020121716401781300_B10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0140-6736(91)90607-Q","article-title":"Heparin treatment in sinus venous thrombosis","volume":"338","author":"Einh\u00e4upl","year":"1991","journal-title":"Lancet"},{"issue":"3","key":"2020121716401781300_B11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/01.STR.30.3.484","article-title":"Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis","volume":"30","author":"de Bruijn","year":"1999","journal-title":"Stroke"},{"issue":"12","key":"2020121716401781300_B12","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamaneurol.2019.2764","article-title":"Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial","volume":"76","author":"Ferro","year":"2019","journal-title":"JAMA Neurol"},{"key":"2020121716401781300_B13","first-page":"e737S","volume-title":"Chest","author":"Monagle","year":"2012"},{"issue":"2","key":"2020121716401781300_B14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2010.08543.x","article-title":"Guideline on the investigation, management and prevention of venous thrombosis in children","volume":"154","author":"Chalmers","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"2020121716401781300_B15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpn.2012.02.005","article-title":"EPNS\/SFNP guideline on the anticoagulant treatment of cerebral sinovenous thrombosis in children and neonates","volume":"16","author":"Lebas","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"issue":"9","key":"2020121716401781300_B16","doi-asserted-by":"crossref","first-page":"e45271","DOI":"10.1371\/journal.pone.0045271","article-title":"Intracerebral hemorrhages in adults with community associated bacterial meningitis in adults: should we reconsider anticoagulant therapy?","volume":"7","author":"Mook-Kanamori","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"2020121716401781300_B17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(07)70131-X","article-title":"Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study","volume":"6","author":"Kenet","year":"2007","journal-title":"Lancet Neurol"},{"issue":"8","key":"2020121716401781300_B18","first-page":"CD002005","article-title":"Anticoagulation for cerebral venous sinus thrombosis","author":"Coutinho","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2020121716401781300_B19","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2020121716401781300_B20","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jth.14813","article-title":"Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation","volume":"18","author":"Young","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2020121716401781300_B21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12959-018-0186-0","article-title":"Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study","volume":"16","author":"Kubitza","year":"2018","journal-title":"Thromb J"},{"issue":"10","key":"2020121716401781300_B22","doi-asserted-by":"crossref","first-page":"e500","DOI":"10.1016\/S2352-3026(19)30161-9","article-title":"Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies","volume":"6","author":"Monagle","year":"2019","journal-title":"Lancet Haematol"},{"issue":"26","key":"2020121716401781300_B23","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"2020121716401781300_B24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2020121716401781300_B25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12959-018-0188-y","article-title":"Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study","volume":"16","author":"Lensing","year":"2018","journal-title":"Thromb J"},{"issue":"11","key":"2020121716401781300_B26","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2020121716401781300_B27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2020121716401781300_B29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.21936","article-title":"Anticoagulants in pediatric cerebral sinovenous thrombosis: a safety and outcome study","volume":"67","author":"Moharir","year":"2010","journal-title":"Ann Neurol"},{"issue":"3","key":"2020121716401781300_B30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1212\/CPJ.0000000000000720","article-title":"Treatment and outcome of childhood cerebral sinovenous thrombosis","volume":"10","author":"Felling","year":"2020","journal-title":"Neurol Clin Pract"},{"issue":"5","key":"2020121716401781300_B31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/STROKEAHA.115.011875","article-title":"Clinical Outcome of Anticoagulant Treatment in Head or Neck Infection-Associated Cerebral Venous Thrombosis","volume":"47","author":"Zuurbier","year":"2016","journal-title":"Stroke"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/24\/6250\/1795575\/advancesadv2020003244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/24\/6250\/1795575\/advancesadv2020003244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T15:06:33Z","timestamp":1724079993000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/24\/6250\/474703\/Safety-and-efficacy-of-rivaroxaban-in-pediatric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":30,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2020,12,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003244","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]}}}